世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ピーナツアレルギー:パイプラインレビュー 2016年下半期

Peanut Allergy - Pipeline Review, H2 2016

 

出版社 出版年月電子版価格 ページ数
Global Markets Direct
グローバルマーケッツダイレクト社
2016年10月US$2,000
シングルユーザライセンス
92

サマリー

Global Markets Directによるピーナツアレルギーのパイプラインレビューです。



Report Details

Peanut Allergy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 5 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Peanut Allergy.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

目次

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peanut Allergy Overview 8
Therapeutics Development 9
Pipeline Products for Peanut Allergy - Overview 9
Pipeline Products for Peanut Allergy - Comparative Analysis 10
Peanut Allergy - Therapeutics under Development by Companies 11
Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 13
Peanut Allergy - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Peanut Allergy - Products under Development by Companies 17
Peanut Allergy - Products under Investigation by Universities/Institutes 18
Peanut Allergy - Companies Involved in Therapeutics Development 19
Adverum Biotechnologies, Inc. 19
Aimmune Therapeutics, Inc. 20
Alfacyte Ltd 21
Allergy Therapeutics Plc 22
AnaptysBio, Inc. 23
Aravax Pty Ltd 24
Array BioPharma Inc. 25
ASIT biotech s.a. 26
Astellas Pharma Inc. 27
BioLingus AG 28
DBV Technologies S.A. 29
HAL Allergy BV 30
Sanofi 31
Peanut Allergy - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
aldesleukin - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Allergen for Peanut Allergy - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Allergen for Peanut Allergy - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Allergen for Peanut Allergy - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ANB-020 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ANN-004 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AR-101 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AR-460770 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
ASP-0892 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
DBV-712 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
HALMPE-1 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
INT-301 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Peanut Allergy Vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
PER-1080 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
pnut-ASIT - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Polyvac Peanut - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Recombinant Protein for Peanut Allergy - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
SCV-204 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
SCV-209 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Vaccine for Peanut Allergy - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
VTC-064 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Peanut Allergy - Dormant Projects 74
Peanut Allergy - Discontinued Products 75
Peanut Allergy - Product Development Milestones 76
Featured News & Press Releases 76
Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results 76
Oct 02, 2016: Immunomic Therapeutics Scientist Presenting at International Society for Vaccines Annual Congress 76
Sep 28, 2016: Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development 76
Sep 20, 2016: Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. 77
Aug 18, 2016: Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children 78
Aug 01, 2016: DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy 79
Jul 05, 2016: DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer 81
Jun 27, 2016: DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children 81
Jun 21, 2016: Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer 82
Jun 21, 2016: DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere 83
Jun 15, 2016: DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression 84
Jun 13, 2016: Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy 85
Jun 07, 2016: Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology Congress 2016 86
Jun 07, 2016: DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board 87
Jun 01, 2016: DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies 88
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る